Vivacelle Bio’s current two products (VBI-1 and VBI-S) are designed to treat hypovolemia that results from acute blood loss following trauma or surgery, medical conditions such as burns, sepsis or diarrheal disease. They are suitable for use in emergency departments, operating rooms, clinics emergency responders and the military.
The total addressable global market for VBI-1 is nearly 33 billion USD for VBI-1 and about 12.8 billion USD for VBI-S globally. In addition to the volume expander or resuscitation fluid market there is also an opportunity to penetrate the blood transfusion market given the fact that a large proportion of blood is given as a volume expander and not because of its ability to deliver oxygen. Another advantage of VBI-1 and VBI-S is that they will be a much a less expensive treatment for hypovolemia given the expense of blood from procurement to administration with a cost of at least $4-6,000/liter. Frequent shortages, along with factors like the need for refrigeration, cross type checking, disease screening and short shelf-life make blood transfusions a difficult treatment to administer in a timely manner for severe hypovolemic subjects in particular. Fresh frozen plasma suffers from similar limitations as well. VBI-1 and VBI-S would also be suitable for volume replacement without blood loss, as is necessary during septic shock from infections or neurogenic shock from spinal cord injuries.
There is no other fluid that addresses both absolute and relative hypovolemia. In addition to addressing absolute and relative hypovolemia phospholipid nanoparticles carry oxygen and reduce organ reperfusion injury in our preclinical studies. In similar studies currently available fluids do not carry oxygen and worsen organ reperfusion injury.